Graft Polymer (UK) PLC Patent Application

RNS Number : 5078Q

Graft Polymer (UK) PLC

31 May 2024

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION WILL BE CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

31 May 2024

Graft Polymer (UK) Plc

("Graft Polymer" or the "Company")

Further Patent Application

 

Filing of US Provisional Patent for Treatment of Mental Health Disorders

 

Graft Polymer (UK) Plc (LSE: GPL) announces that it has filed a second utility patent application (provisional) with the United States Patent and Trademark Office (USPTO). This application is for the use of the Company's proprietary and patented self-nanoemulsifying drug delivery systems (SNEDDS) platform for the delivery of drugs for the treatment of mental health disorders such as Generalised Anxiety Disorder (GAD), Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD).

 

 

Patent Filing Overview

The provisional patent application, titled 'Composition and methods for mental health disorders using a self-nanoemulsifying drug delivery systems (SNEDDS)', covers the innovative application of Graft Polymer's SNEDDS platform to enhance the bioavailability, pharmacokinetics and stability of therapeutics used in the treatment of health disorders such as GAD, MDD and PTSD, many of which have poor solubility leading to suboptimal drug delivery and posing an obstacle to successful formulation. This approach aims to leverage the Company's existing advanced biopolymer expertise to address significant unmet medical needs in addiction therapy.

 

 

Strategic Significance

The filing of this patent follows the announcement, by the Company, on 28 May 2024 relating to the filing of a similar utility patent application (provisional) for the treatment of substance use disorders. It marks further progress in the Company's strategic focus on the healthcare industry, following the disposal of its industrial plastic manufacturing unit, Graft Polymer D.O.O, as announced on 3 May 2024. This disposal has enabled the Company to focus its attention and resources on its Graft Bio division, which represents, in the Directors' opinion, strong prospectivity through its intellectual property (IP), licensing agreements, and sales contracts.

 

 

Anthony Tennyson, CEO commented:

"We are delighted to announce further progress in leveraging our existing biopolymer intellectual property for additional important healthcare applications with substantial unmet medical needs."

 

 

Enquiries

Graft Polymer (UK) Plc
Anthony Tennyson, CEO and Executive Director
Email: [e-mail]

Yifat Steuer, CFO and Executive Director
Email: [e-mail]

 

Allenby Capital (Broker)

Nick Naylor / Liz Kirchner (Corporate Finance) 

Guy McDougall (Sales) 

 [phone] 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

RAPBDGDUSUXDGSG